Neuropathic pain common among breast cancer survivors in Belgian study

  • Leysen L & al.
  • Pain Pract
  • 30 Sep 2018

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Neuropathic pain is the most common individual chronic pain type among breast cancer survivors.
  • Central sensitization pain is more common among recipients of hormone therapy.

Why this matters

  • Breast cancer (BCa) survivors with chronic pain should be referred to pain specialists.
  • Hormone therapy recipients should be advised of the risk of central sensitization pain.

Study design

  • Cross-sectional cohort (n=91) of BCa patients with chronic pain.
  • Pain type was studied by Visual Analog Scale for pain (VAS), Douleur Neuropathique 4 Questionnaire (DN4), Margolis Pain Diagram, Central Sensitization Inventory (CSI).
  • Pain effect on health-related QoL (HRQoL) was studied by Short form 36 (SF-36).
  • Funding:  No external sources.

Key results

  • Neuropathic pain and mixed pain were the most common pain types:
    • neuropathic pain, 25.3%;
    • nociceptive pain, 18.7%;
    • central sensitization, 15.4%; and
    • mixed pain (any combination of neuropathic, nociceptive, and/or central sensitization), 40.6%.
  • The pain groups were significantly different in HRQoL "general health" subscale by one-way analysis of variance (P=.04).
  • Central sensitization was nearly 26 times more common among hormone therapy recipients than nonrecipients (OR, 25.95; P=.03).

Limitations

  • Cross-sectional, observational design.
  • Small number of subjects.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit